19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM reports Phase II data for NGM282 in primary sclerosing cholangitis

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported additional data from a Phase II trial in 62 primary sclerosing cholangitis (PSC) patients with elevated alkaline phosphatase levels showing that once-daily subcutaneous 3 mg NGM282 significantly...
19:32 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM's NGM282 meets in Phase II data for NASH

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported data from a single-blind Phase II trial in 19 non-alcoholic steatohepatitis (NASH) patients showing that once-daily subcutaneous 3 mg NGM282 met the primary endpoint of reducing absolute...
19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other molecule...
03:08 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

Ghrelin’s LEAP forward

NGM and MedImmune researchers have discovered a liver peptide, LEAP2, that is a natural antagonist of the metabolic target ghrelin. The peptide could serve as a new handle for either boosting or dampening ghrelin signaling...
19:21 , Oct 18, 2017 |  BC Extra  |  Preclinical News

Amgen team describes GDF15's role in obesity

In a paper published Wednesday in Science Translational Medicine, researchers from Amgen Inc. (NASDAQ:AMGN) showed the involvement of growth differentiation factor 15 (GDF15) in regulating body weight in mice, rats, and non-human primates. Amgen is the...
19:43 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity; cachexia Mouse and rat studies suggest GDF15 could help treat obesity, and inhibiting its receptor GFRAL could help treat cachexia. In a mouse model of high-fat diet-induced obesity and a genetic rat model of...
23:12 , Oct 2, 2017 |  BC Extra  |  Preclinical News

NGM targeting GFRAL for both obesity and cachexia

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) plans to develop separate candidates modulating GDNF family receptor alpha like (GFRAL) to treat both obesity and cachexia. In a newly published paper, an NGM team showed GFRAL...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other molecule...
16:02 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Patient sample and mouse studies suggest inhibiting the IL-6-JAK-STAT3 axis could help treat FGF19-driven hepatocellular cancer (HCC). In HCC patients, high tumor levels of FGF19 were associated with poor overall survival and...